What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Obesity & overweight › maridebart cafraglutide

maridebart cafraglutide in obesity & overweight

maridebart cafraglutide is not approved in the US for obesity & overweight, and has 10 trials on file here in this condition. 8 of them are phase 3 or later. The next scheduled result is 2027-01-21. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

10 registered trials study maridebart cafraglutide in obesity & overweight, 9 of them still active and 8 in phase 3. The next is due to report 2027-01-21.

Trials on file
10
Active
9
Active phase 3
8
Participants in active trials
26,868
Sponsors
1
Scheduled readouts
9

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completionTrialPhaseParticipants
2027-01-21Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839 · Amgen
P33,853
2027-04-27Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
NCT06987695 · Amgen
P3279
2027-09-29A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 · Amgen
P2180
2027-09-29Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686 · Amgen
P3250
2027-12-26Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235 · Amgen
P33,200
2027-12-26Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144 · Amgen
P3950
2028-01-03Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399 · Amgen
P3300
2028-06-30Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 · Amgen
P312,800
2028-06-30Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 · Amgen
P35,056

All trials on file

Every registered trial of maridebart cafraglutide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433
RecruitingP3Amgen
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459
RecruitingP3Amgen
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839
Active, not recruitingP3Amgen
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235
RecruitingP3Amgen
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144
RecruitingP3Amgen
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
NCT05669599
CompletedP2Amgen
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399
RecruitingP3Amgen
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
NCT06987695
Active, not recruitingP3Amgen
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686
RecruitingP3Amgen
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252
RecruitingP2Amgen

See the full record for maridebart cafraglutide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.